ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Fight Back! Win the War Being Waged Against Your Immune System

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Pumpkin Pie Turmeric Breakfast Smoothie - Vegan + Gluten-Free

Vitamin D supplementation extends life in mouse model of Huntington's disease

What’s Fenugreek Good For?

Omega-3 fatty acid stops known trigger of lupus

Print Page
Email Article

Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome

  [ 1 vote ]   [ Discuss This Article ] • August 21, 2013

Editor's comment: Cyclobenzaprine is probably best known by the brand name Flexeril, which is currently classified as a muscle relaxant. 

Data Elucidate Cyclobenzaprine as a Serotonin and Norepinephrine Receptor Antagonist and Reuptake Inhibitor (SNARI)

NEW YORK, NY – August 19, 2013 – Tonix Pharmaceuticals Holding Corp. (TNXP), a specialty pharmaceutical company developing novel treatments for challenging disorders of the central nervous system (CNS), including fibromyalgia and post-traumatic stress disorder (PTSD), presented results from nonclinical studies of cyclobenzaprine (CBP), the active ingredient of Tonix's lead candidate, TNX-102 sublingual tablet (TNX-102 SL), at the International Pain Society's Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome in Seattle, Washington.

The presentation, titled "Cyclobenzaprine (CBP) Inhibits Serotonin (5HT) Receptor Type 2A, Adrenergic Receptor alpha1A and the 5HT and Norepinephrine (NE) Reuptake Transporters: Mechanistic Implications for Treating Fibromyalgia Syndrome and Post-traumatic Stress Disorder (PTSD) by Improving Sleep Quality," was given by Bruce Daugherty, Ph.D., Tonix's Chief Scientific Officer and the study's lead author, on Friday, August 16, at 1:45 PM Pacific Time.

As observed in nonclinical studies conducted under Tonix's direction, CBP and its major metabolite, norcyclobenzaprine (nCBP), exhibited potent binding (Ki) to certain CNS receptors including 5HT2A (5.2 and 13 nM, respectively), adrenergic alpha1A (5.6 and 34 nM), and histamine H1 (1.3 and 5.9 nM). In addition, CBP and nCBP are functional antagonists (IC50) at 5HT2A (230 and 140 nM, respectively), alpha1A (4.9 and 16 nM, respectively), and H1 (5.2 and 16 nM, respectively). CBP and nCBP also exhibited potent binding to the serotonin (35 and 2.6 nM, respectively) and norepinephrine (29 and 91 nM, respectively) monoamine reuptake transporters.

Dr. Daugherty commented, "We have significantly advanced our understanding of the mechanisms of action of CBP in the CNS. We have shown that CBP exerts multiple effects on serotonergic and adrenergic neurotransmission. As a Serotonin and Norepinephrine Receptor Antagonist and Reuptake Inhibitor, or SNARI, we believe TNX-102 SL exerts pharmacological effects distinct from those exerted by products approved by the Food and Drug Administration for the management of fibromyalgia and PTSD. We look forward to commencing our Phase 2b/3 trial of TNX-102 SL in patients with fibromyalgia this quarter." 

About Tonix Pharmaceuticals Holding Corp. Tonix is developing innovative prescription medications for challenging disorders of the central nervous system. The Company seeks to address conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among patients and physicians. Tonix's lead pharmaceutical candidate, TNX-102 SL, targets central pain. Fibromyalgia is a central pain syndrome, and central pain is a component of post-traumatic stress disorder. Tonix applies its core technology toward the treatment of central pain by increasing the restorative power of sleep. To learn more, please visit

Source: Tonix Pharmaceuticals, Press Release, August 19, 2013.

Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Ultra ATP+, Double Strength Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Secret Nutrient for Radiant Skin Secret Nutrient for Radiant Skin
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
How to Jump-start and Sustain Energy Production in CFS How to Jump-start and Sustain Energy Production in CFS
Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue
Carry a Massage Therapist in Your Pocket Carry a Massage Therapist in Your Pocket

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map